Inclusion Criteria:

          -  Male or females ≥ 18 years old with the ability to take oral drugs

          -  Diagnosis of advanced HCC according to the American Association for the Study of Liver
             Diseases (AASLD) Guidelines (Heimbach et al. 2018) or diagnosis by tissue pathology

          -  Life expectancy of at least 3 months

          -  Presence of chronic hepatitis B (HBsAg (+) and IgM anti-HBc (-))

          -  Never received systemic antitumor therapy

          -  Patients must have at least one tumor lesion that meets both of the following
             criteria:

               -  "Measurable disease" according to RECIST 1.1 , i.e. at least one measurable
                  lesion.

               -  Advanced unresectable HCC that have liver limited disease who have failed or not
                  candidates to local therapies including surgery and local-regional therapies; or
                  patients with extrahepatic disease.

          -  Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤1

          -  Cirrhotic status of current Child-Pugh class A. Child-Pugh status should be calculated
             based on clinical findings and laboratory results during the screening period

          -  For patients with positive HBV-DNA and/or positive HBsAg results, they must be treated
             with antivirals (per local standard of care), as prophylaxis starting at least 1-2
             weeks prior to receiving study drug and willingness to continue treatment for the
             length of the study.

          -  Patients with adequate organ reserve, such as laboratory parameters:

               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9/L

               -  Platelets ≥ 60000 x 10^6/L

               -  Hemoglobin (Hgb) ≥ 9 g/dL

               -  Serum alanine amino-transferase (ALT) ≤ 5 x ULN

          -  Adequate renal function, based upon meeting the following laboratory criteria within 7
             days before randomization:

               -  Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 40mL/min (using
                  the Cockroft-Gault equation: (140-age) x weight (kg)/(serum creatinine x 72
                  [mg/dL] for males. (For females multiply by 0.85) AND

               -  24-hour urine protein <1 g

          -  Ability to understand and willingness to sign a written informed consent and to be
             able to follow the visit schedule

        Exclusion Criteria:

          -  Patients who ever have HCV infection

          -  Patients who have received systemic chemo-therapies or immunotherapy or molecular
             target therapies

          -  Patients who have received any local anti-cancer therapy within 4 weeks prior to Cycle
             1 treatment

          -  Active bleeding (including gastrointestinal bleeding, encephalopathy, and ascites)
             during the last 4 weeks prior to Cycle 1 treatment

          -  Patients with a history of allergy to the known components of YIV-906

          -  Known history of human immunodeficiency virus (HIV) seropositivity

          -  Known central nervous system metastasis including brain metastasis and meningeal
             carcinomatosis

          -  Hepatocholangiocarcinoma, fibrolamellar cell carcinoma and mixed hepatocellular
             carcinoma

          -  Active malignancy (except for definitively treated melanoma in-situ, basal or squamous
             cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 5
             years

          -  Any severe and/or uncontrolled medical conditions including but not limiting to:

               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction ≤ 6 months prior to Cycle 1 treatment, serious uncontrolled cardiac
                  arrhythmia, uncontrolled hypertension

               -  Previous transient ischemic attack (TIA), cerebral vascular accident (CVA),
                  symptomatic peripheral vascular disease (PVD) within last 6 months of Cycle 1
                  treatment

               -  Congenital long QT syndrome

               -  Alcoholic patients

               -  Acute and chronic, active infectious disorders and nonmalignant medical illnesses
                  that are uncontrolled or whose control may be jeopardized by this study therapy,
                  in the opinion of the investigator, except chronic HBV

               -  Impairment of gastrointestinal function or who have a gastrointestinal disease
                  that may significantly alter the absorption of study drugs (e.g., ulcerative
                  disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)

               -  Patients who have had organ transplantation

          -  Patients receiving chronic treatment with corticosteroids (except for intermittent
             topical or local injection or aldosterone) or other immunosuppressive agent Subjects
             receive any blood transfusion, albumin transfusion, erythropoietin (EPO), granulocyte
             colony-stimulating factor (G-CSF), TPO or other medical supportive treatment prior to
             Cycle 1 treatment

          -  Patients treated with drugs known to be strong inducers of isoenzyme CYP3A within 7
             days of Cycle 1 treatment

          -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
             who have not recovered from surgery

          -  Patients who have received an investigational drug or therapy within the last 4 weeks
             prior to Cycle 1 treatment.

          -  Pregnant and/or breastfeeding women

          -  Men and women of childbearing age and potential, who are not willing to use effective
             contraception

          -  Unwilling or unable to follow protocol requirements or to give informed consent

          -  An ongoing or recent history of autoimmune, uncontrolled psychiatric disorders and
             drug abuse

          -  Uncontrolled hereditary or acquired thrombotic or bleeding disorder

          -  Bowel obstruction, history or presence of inflammatory enteropathy or extensive
             intestinal resection

          -  Therapeutic dose anticoagulation with warfarin or similar agents

          -  Chronic therapy with nonsteroidal anti-inflammatory agents or other antiplatelet
             agents. Aspirin at doses up to 100 milligrams/day is permitted

          -  Patients with an estimated or calculated baseline creatinine clearance of less than 40
             mL/min should not be enrolled in this trial

          -  No patient, however, may enroll in this trial if they are taking phenytoin (Dilantin)

          -  Patients taking traditional Chinese medicines within 14 days prior to taking first
             dose of study treatment